Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete | ||
Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
Pemazyre | pemigatinib | Cholangiocarcinoma | Active | |||
Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
Perjeta Herceptin Combo Pack | Pertuzumab | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete | ||
Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
Perseris | risperidone | Schizophrenia, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Pheburane | Sodium phenylbutyrate | Urea cycle disorders | List | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
Plegridy | Peginterferon beta-1a | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Pluvicto | lutetium vipivotide tetraxetan | Metastatic castration-resistant prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | ||
Polivy Resubmission | polatuzumab vedotin | large B-cell lymphoma (LBCL) | Pending | |||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Poteligeo | mogamulizumab | mycosis fungoides (MF), Sézary syndrome (SS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete |